NCT04875806

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: NextCure, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

Conditions

• Advanced or Metastatic Solid Tumors
• Ovarian Cancer
• Non-small Cell Lung Cancer
• Breast Cancer

Interventions

Type	Name	Description
DRUG	NC762	NC762 is an experimental antibody drug that may make the immune response more active against cancer

Timeline

• Start date: 2021-06-30
• Primary completion: 2024-01-30
• Completion: 2024-01-30
• First posted: 2021-05-06
• Last updated: 2025-04-22
• Results posted: 2025-04-22

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study